AI-Enabled POC Device Detects Cancers Without Biopsies
|
By LabMedica International staff writers Posted on 15 Sep 2022 |

Researchers have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell. Loaded with light scattering dyes called Raman reporters commonly used to detect biomarkers of disease in organic samples, the approach can amplify and detect signals from separate types of nanoprobes without needing an expensive machine or medical professional to read the results. In a small proof-of-concept study, the nanorattles accurately identified head and neck cancers through an AI-enabled point-of-care device that could revolutionize how these cancers and other diseases are detected in low-resource areas to improve global health.
To make nanorattles, researchers at Duke University (Durham, NC, USA) start with a solid gold sphere about 20 nanometers wide. After growing a layer of silver around the gold core to make a larger sphere (or cube), they use a corrosion process called galvanic replacement that hollows out the silver, creating a cage-like shell around the core. The structure is then soaked in a solution containing positively charged Raman reporters, which are drawn into the outer cage by the negatively charged gold core. The outer hulls are then covered by an extremely thin layer of gold to lock the Raman reporters inside. The result is a nanosphere (or nanocube) about 60 nanometers wide with an architecture that resembles a rattle - a gold core trapped within a larger outer silver-gold shell. The gap between the two is only about a few nanometers, which is just large enough to fit the Raman reporters. Those tight tolerances are essential to controlling the Raman signal enhancement the nanorattles produce.
When a laser shines on the nanorattles, it travels through the extremely thin outer shell and hits the Raman reporters within, causing them to emit light of their own. Because of how close the surfaces of the gold core and the outer gold/silver shell are together, the laser also excites groups of electrons on the metallic structures, called plasmons. These groups of electrons create an extremely powerful electromagnetic field due to the plasmons’ interaction of the metallic core-shell architecture, a process called plasmonic coupling, which amplifies the light emitted by the Raman reporters millions of times over. The researchers applied the nanorattle technology to a lab-on-a-stick device capable of detecting head and neck cancers, which appear anywhere between the shoulders and the brain, typically in the mouth, nose and throat. Survival rate for these cancers have hovered between 40 and 60% for decades. While those statistics have improved in recent years in the U.S., they have gotten worse in low-resource settings, where risk factors such as smoking, drinking and betel nut chewing are much more prevalent.
The prototype device uses specific genetic sequences that act like Velcro for the biomarkers the researchers are looking for - in this case, a specific mRNA that is overly abundant in people with head and neck cancers. When the mRNA in question is present, it acts like a tether that binds nanorattles to magnetic beads. These beads are then concentrated and held in place by another magnet while everything else gets rinsed away. Researchers can then use a simple, inexpensive handheld device to look for light emitted from the nanorattles to see if any biomarkers were caught. In the experiments, the test determined whether or not 20 samples came from patients that had head and neck cancer with 100% accuracy. The experiments also showed that the nanorattle platform is capable of handling multiple types of nanoprobes, thanks to a machine learning algorithm that can tease apart the separate signals, meaning they can target multiple biomarkers at once.
“In low-resource settings, these cancers often present in advanced stages and result in poor outcomes due in part to limited examination equipment, lack of trained healthcare workers and essentially non-existent screening programs,” said Walter Lee, professor of head and neck surgery & communication sciences and radiation oncology at Duke, and a collaborator on the research. “Having the ability to detect these cancers early should lead to earlier treatment and improvement in outcomes, both in survival and quality of life,” Lee said. “This approach is exciting since it does not depend on a pathologist review and potentially could be used at the point of care.”
“Many mRNA biomarkers are overly abundant in multiple types of cancers, while other biomarkers can be used to evaluate patient risk and future treatment outcome,” said Tuan Vo-Dinh, the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering and professor of chemistry at Duke. “Detecting multiple biomarkers at once would help us differentiate between cancers, and also look for other prognostic markers such as Human Papillomavirus (HPV), and both positive and negative controls. Combining mRNA detection with novel nanorattle biosensing will result in a paradigm shift in achieving a diagnostic tool that could revolutionize how these cancers and other diseases are detected in low-resource areas”.
Related Links:
Duke University
Latest Molecular Diagnostics News
- AI-Supported Approach May Improve Cervical Cancer Screening in Low-Resource Settings
- Molecular AI Model Refines Risk Prediction in Pediatric Brain Tumors
- Multiplex PCR Panel Gains FDA Clearance for Viral Hemorrhagic Fever Detection
- Blood Test Identifies Early Breast and Prostate Cancer Signals Years Before Diagnosis
- Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer
- Liquid Biopsy Measures Tumor Burden and Identifies Small Cell Lung Cancer Subtypes
- Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
- Rapid Lab-Free UTI Test Enters First Use in Care Home Setting
- Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
- New NGS Panel Detects AML Fusions at MRD-Level Sensitivity
- Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings
- Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer
- Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment
- RNA Sequencing Assay Gains EU Certification for Solid Tumor Profiling
- Whole-Genome MRD Test Detects Traces of Cancer During and After Treatment
- Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer
Channels
Clinical Chemistry
view channel
Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more
Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more
Blood-Based Score May Support Targeted Interventions for Healthier Aging
Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more
Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read moreMicrobiology
view channel
Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more
Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more
Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read more
Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
PCR amplifies DNA to enable highly accurate testing, but its reliance on complex, expensive laboratory analyzers has traditionally kept many workflows in centralized settings. A new personal DNA analyzer... Read moreIndustry
view channel
Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
Singapore’s National Precision Medicine program is using genomic and health data to support more preventive and personalized healthcare. Its latest phase expands beyond healthy volunteers to people with... Read more







